CA2626565A1 - Piperazine derivatives useful as ccr5 antagonists - Google Patents

Piperazine derivatives useful as ccr5 antagonists Download PDF

Info

Publication number
CA2626565A1
CA2626565A1 CA002626565A CA2626565A CA2626565A1 CA 2626565 A1 CA2626565 A1 CA 2626565A1 CA 002626565 A CA002626565 A CA 002626565A CA 2626565 A CA2626565 A CA 2626565A CA 2626565 A1 CA2626565 A1 CA 2626565A1
Authority
CA
Canada
Prior art keywords
mmol
compound
ch2ci2
solution
product
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002626565A
Other languages
English (en)
French (fr)
Inventor
Ragulan Ramanathan
Anima Ghosal
Michael W. Miller
Swapan K. Chowdhury
Kevin B. Alton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2626565A1 publication Critical patent/CA2626565A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Communicable Diseases (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
CA002626565A 2005-10-21 2006-10-18 Piperazine derivatives useful as ccr5 antagonists Abandoned CA2626565A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11/255,643 US7825121B2 (en) 1999-05-04 2005-10-21 Piperazine derivatives useful as CCR5 antagonists
US11/255,643 2005-10-21
PCT/US2006/040636 WO2007050375A2 (en) 2005-10-21 2006-10-18 Piperazine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
CA2626565A1 true CA2626565A1 (en) 2007-05-03

Family

ID=37872167

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002626565A Abandoned CA2626565A1 (en) 2005-10-21 2006-10-18 Piperazine derivatives useful as ccr5 antagonists

Country Status (17)

Country Link
US (1) US7825121B2 (enExample)
EP (1) EP1951708B1 (enExample)
JP (2) JP2009512705A (enExample)
KR (1) KR20080058486A (enExample)
CN (1) CN101326178A (enExample)
AR (1) AR058105A1 (enExample)
AU (1) AU2006306491B2 (enExample)
BR (1) BRPI0617731A2 (enExample)
CA (1) CA2626565A1 (enExample)
EC (1) ECSP088378A (enExample)
IL (1) IL190902A0 (enExample)
NO (1) NO20082297L (enExample)
PE (1) PE20070711A1 (enExample)
RU (1) RU2008119652A (enExample)
TW (1) TW200800234A (enExample)
WO (1) WO2007050375A2 (enExample)
ZA (1) ZA200803454B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2562235C (en) 2004-04-13 2013-09-24 Incyte Corporation Piperazinylpiperidine derivatives as chemokine receptor antagonists
ES2340531T3 (es) * 2005-10-21 2010-06-04 Glaxo Group Limited Compuestos triciclos peri-condensados utiles como agentes antibacterianos.
US20080108586A1 (en) * 2006-09-06 2008-05-08 Incyte Corporation Combination therapy for human immunodeficiency virus infection
WO2010081851A1 (en) 2009-01-14 2010-07-22 Genoscience Pharma Piperidin-4-ylpiperazine compounds for the treatment of hcv infection
DK2683643T3 (da) 2011-03-09 2019-08-12 Richard G Pestell Prostatacancercellelinjer, gensignaturer og anvendelser deraf
GB201118876D0 (en) 2011-11-01 2011-12-14 Astex Therapeutics Ltd Pharmaceutical compounds
CN104853806A (zh) 2012-05-14 2015-08-19 理查德·G·佩斯泰尔 使用ccr5调节剂治疗癌症
WO2016094011A1 (en) * 2014-12-11 2016-06-16 Merck Sharp & Dohme Corp. Crystal forms of a ccr5 antagonist
US12459808B2 (en) 2021-09-13 2025-11-04 Kabushiki Kaisha Toshiba Sensor

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6391865B1 (en) * 1999-05-04 2002-05-21 Schering Corporation Piperazine derivatives useful as CCR5 antagonists
DE60021370C5 (de) 1999-05-04 2007-11-08 Schering Corp. Piperazinderivate verwendbar als ccr5 antagonisten
AU2002303168B2 (en) 2001-03-29 2005-10-06 Schering Corporation Aryl oxime-piperazines useful as ccr5 antagonists

Also Published As

Publication number Publication date
CN101326178A (zh) 2008-12-17
PE20070711A1 (es) 2007-08-11
BRPI0617731A2 (pt) 2011-08-02
RU2008119652A (ru) 2009-11-27
JP2012072195A (ja) 2012-04-12
EP1951708B1 (en) 2013-11-20
WO2007050375A2 (en) 2007-05-03
ZA200803454B (en) 2009-04-29
AR058105A1 (es) 2008-01-23
AU2006306491B2 (en) 2012-12-13
AU2006306491A1 (en) 2007-05-03
WO2007050375A3 (en) 2007-06-14
US7825121B2 (en) 2010-11-02
JP2009512705A (ja) 2009-03-26
TW200800234A (en) 2008-01-01
US20060105964A1 (en) 2006-05-18
EP1951708A2 (en) 2008-08-06
KR20080058486A (ko) 2008-06-25
NO20082297L (no) 2008-07-21
IL190902A0 (en) 2008-11-03
ECSP088378A (es) 2008-05-30

Similar Documents

Publication Publication Date Title
CA2371583C (en) Piperazine derivatives useful as ccr5 antagonists
US6391865B1 (en) Piperazine derivatives useful as CCR5 antagonists
US6689765B2 (en) Piperazine derivatives useful as CCR5 antagonists
US20040092745A1 (en) Piperidine derivatives useful as CCR5 antagonists
JP2012072195A (ja) Ｃｃｒ５アンタゴニストとして有用なピペラジン誘導体
CN100490811C (zh) 用作ccr5拮抗剂的哌嗪衍生物
HK1088001A (en) Piperazine derivatives useful as ccr5 antagonists
MXPA01011185A (en) Piperazine derivatives useful as ccr5 antagonists
HK1061563B (en) Piperidine derivatives useful as ccr5 antagonists for the treatment of hiv

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued

Effective date: 20150415